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 Introduction 
 Alcohol dependence (AD) is a clinical disorder char-
acterised by a cluster of physiological, psychological, be-
havioural and cognitive phenomena in which alcohol 
consumption takes on a much higher priority for an in-
dividual than other behaviours and obligations  [1, 2] . 
Formally diagnosed by the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) and/or the World 
Health Organisation’s (WHO) International Classifica-
tion of Diseases (ICD-10)  [3, 4] , AD is one of the most 
common disorders of the central nervous system in the 
European Union (EU), with an estimated annual preva-
lence of between 3 and 4%  [5, 6] . The high prevalence of 
AD corresponds to the high level of alcohol consumption 
in this region; the EU is the heaviest drinking region in 
the world and had an estimated adult per capita con-
sumption level of 12.4 l in 2009, which was more than 
twice the global average  [7] .
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 Abstract 
 Background: Alcohol consumption is one of the most im-
portant factors for disease and disability in Europe. In clinical 
trials, nalmefene has resulted in a significant reduction in the 
number of heavy-drinking days (HDDs) per month and total 
alcohol consumption (TAC) among alcohol-dependent pa-
tients versus placebo.  Methods: A microsimulation model 
was developed to estimate alcohol-attributable diseases 
and injuries in patients with alcohol dependence and to ex-
plore the clinical relevance of reducing alcohol consump-
tion.  Results: For all diseases and injuries considered, the 
number of events (inpatient episodes) increased with the 
number of HDDs and TAC per year. The model predicted that 
a reduction of 20 HDDs per year would result in 941 fewer 
alcohol-attributable events per 100,000 patients, while a re-
duction in intake of 3,000 g/year of pure alcohol (ethanol) 
would result in 1,325 fewer events per 100,000 patients. 
 Conclusion: The potential gains of reducing consumption in 
alcohol-dependent patients were considerable. 
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 AD has adverse consequences for both individual 
health and for society  [8] . The risk of alcohol-related 
mortality has been shown to increase almost exponen-
tially as alcohol consumption increases, both for lifetime 
risk and absolute annual risk, with the absolute annual 
risk for chronic disease mortality almost doubling as al-
cohol consumption increases from 10 to 100 g/day  [9] . 
Therefore, for people with AD with a high level of con-
sumption, the mortality risks are manifold compared to 
abstainers, low- or moderate-level drinkers  [10] . Alcohol 
use is also one of the greatest risk factors in Europe for 
disease and disability, with causal relationships existing 
between alcohol consumption and more than 200 types 
of disease and injury  [11–13] . The risk of developing al-
cohol-attributable diseases and injuries increases with 
higher levels of alcohol consumption in a dose-depen-
dent manner, while the pattern in which alcohol is con-
sumed in terms of the frequency of heavy-drinking days 
(HDDs) also contributes to individual risk  [14–16] . The 
risks of many negative social consequences of alcohol 
(such as physical violence and dysfunctional marriage, 
home life, working life and social life) also increase, often 
exponentially, with the amount of alcohol consumed 
 [17] .
 The adverse consequences of alcohol consumption 
place a major economic strain on the individual and so-
ciety  [18–21] . One recent report estimated alcohol-relat-
ed costs in the EU to be EUR 155.8 billion in 2010; this 
estimate included both the direct and indirect costs of 
alcohol consumption, encompassing the healthcare costs 
of alcohol-related diseases and injuries, judicial costs, 
and costs associated with the loss of productivity from 
unemployment, absenteeism and premature retirement 
or mortality  [16] . AD is estimated to account for approx-
imately 60% of total alcohol-related costs  [22] , although 
it is likely that this is an underestimate due to the major-
ity of alcohol-dependent patients being undiagnosed 
 [16] .
 Given the relationship between alcohol consumption 
and the risks of alcohol-attributable mortality, disease 
and injury, it is likely that reducing total alcohol con-
sumption (TAC) and the number of HDDs would lead to 
a reduction in the alcohol-attributable health burden 
 [16] . While traditional management regimes for AD have 
tended to focus on promoting abstinence through inter-
ventions such as cognitive behavioural therapy and phar-
macotherapy, the more recent and alternative ‘harm re-
duction approach’ attempts to help patients achieve a re-
duction in consumption without the need to abstain from 
alcohol entirely. The latter approach is now widely recog-
nised as a valid treatment goal for alcohol-dependent pa-
tients, with reductions in TAC and the number of HDDs 
being recognised by the European Medicines Agency 
(EMA) as two primary endpoints relevant for assessing 
the success of interventions designed to enable this treat-
ment approach  [19] .
 The European Commission recently granted market-
ing authorisation for nalmefene for the reduction of alco-
hol consumption in adult patients with AD who have a 
high drinking risk level (DRL) according to the WHO 
(>60 g/day of pure alcohol for men, >40 g/day for women) 
without physical withdrawal symptoms, and who do not 
require immediate detoxification  [19, 20] . Nalmefene 
should only be prescribed in conjunction with continu-
ous psychosocial support focused on treatment adher-
ence and reducing alcohol consumption, and it should 
only be initiated in patients who continue to have a high 
DRL 2 weeks after their initial assessment  [23] . Nalmefene 
has demonstrated efficacy in reducing both TAC and the 
number of HDDs per month in alcohol-dependent 
 patients in three phase III clinical trials: ESENSE1 
(NCT00811720), ESENSE2 (NCT00812461) and SENSE 
(NCT00811941)  [24–28] . However, the clinical trials 
were not designed to demonstrate the impact of nal-
mefene on the incidence of alcohol-attributable diseases 
and injuries.
 Evidence exists in the literature from a large number 
of time-series analyses and natural experiments that re-
ductions in alcohol consumption lead to reduced mortal-
ity on a population level  [10, 29–33] . These natural ex-
periments include analyses of the effects of prohibition or 
other political measures to reduce population alcohol 
consumption, such as taxation increases, on population 
mortality rates. Inevitably, many such studies are corre-
lational only. Scenario modelling is an original approach 
that has recently been used to ascertain the positive effects 
of strategies to reduce alcohol consumption on mortality. 
For instance, in one analysis the consequences of provid-
ing pharmacotherapy to 40% of alcohol-dependent pa-
tients in the EU were predicted to lead to a reduction of 
11,740 deaths in the first year  [16, 34] .
 The aim of the current analysis is to develop a predic-
tive microsimulation model to estimate the risks of al-
cohol-attributable diseases and injuries occurring at 
different alcohol consumption levels. The model can 
then be used to evaluate the clinical relevance of reduc-
ing alcohol consumption in terms of the number of al-
cohol-attributable diseases or injuries avoided. While 
previous work in this area has tended to investigate the 
health of general populations in relation to alcohol con-
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sumption  [16, 35] , this model focuses on alcohol con-
sumption specifically in alcohol-dependent individuals, 
with the risk of various alcohol-attributable diseases 
and injuries modelled for each individual based on their 
simulated alcohol consumption. A microsimulation ap-
proach enables more accurate modelling of individual 
variation in patient characteristics and has been used 
for modelling a number of diseases, such as cancer and 
obesity  [36–38] . During the EMA marketing authorisa-
tion process for nalmefene, this model was presented to 
the Committee for Medicinal Products for Human Use 
(CHMP) to demonstrate the clinical relevance of reduc-
tion of alcohol consumption with the use of the medi-
cine  [39] .
 Methods 
 Model Overview 
 A predictive microsimulation model using England as the ref-
erence case simulated the alcohol consumption of individual pa-
tients, day by day for 12 months, using statistical equations esti-
mated from nalmefene clinical trial data on alcohol consumption 
in patients from 19 European countries. No treatment effect of 
nalmefene was considered in the model as data on alcohol con-
sumption from clinical trials were taken from the month prior to 
baseline assessment when patients were screened before com-
mencing treatment. The model used English hospitalisation data 
to derive the incidence of alcohol-attributable diseases and injuries 
in the general population. The relative risks of such clinical events 
for each patient in the model, based on their simulated alcohol 
consumption and the incidence of events in the general popula-
tion, were derived from published international epidemiological 
studies measuring the association between level of alcohol con-
sumption and the risk of alcohol-attributable injuries or diseases 
 [11, 40–51] . A summary of the main inputs to the microsimulation 
model is shown in  figure 1 .
 The model outcomes (‘events’) were inpatient consultation ep-
isodes for a specific alcohol-attributable disease or injury ( fig. 1 ). 
Probabilities of clinical events occurring were compared between 
categories of patients defined according to the number of modelled 
HDDs and TAC over the 12-month simulation period. An HDD 
was defined as a day with consumption of 60 g of pure alcohol or 
more for men and 40 g or more for women, in line with WHO cri-
teria for high and very high DRLs  [19, 20] . TAC was equal to the 
sum of the number of grams of pure alcohol consumed per patient 
per day over the course of 1 year. The number of HDDs across 1 
year was divided into eight categories with a range of 20 HDDs per 
year, representing a difference of approximately two HDDs per 
month between successive HDD categories. TAC per year was di-
vided into 14 categories with a difference of 3,000 g per year be-
tween each successive category, in order to represent a difference 
between successive categories of approximately 10 g/day.
 The model was programmed in Scilab version 5.3.3  [52] . Re-
sults are presented per 100,000 patients per drinking category, and 
have been adjusted for the proportion of males and females in the 
clinical trials (68.6 and 31.4%, respectively). To provide some con-
text for the clinical relevance of reductions in alcohol consump-
tion, the model results were considered in light of results from the 
three nalmefene phase III clinical trials for the licensed popula-
tion.
 Simulating Alcohol Consumption 
 A two-part statistical model based on two generalised linear 
mixed models (GLMMs) was constructed to predict alcohol con-
sumption each day  [53, 54] . The first part was a logistic model pre-
dicting the probability of drinking any alcohol over 1 day as a func-
tion of patient characteristics and other factors identified as influ-
encing alcohol consumption. Factors identified as influencing 
alcohol consumption included age, gender, day of the week, coun-
try and treatment history. In addition, alcohol consumption on a 
given day was found to be influenced by alcohol consumption dur-
ing previous days, with log-transformed values of alcohol con-
sumption the day before, 2 and 7 days before being significant pre-
dictors. The specific form of the logistic model for the reference 
case is given in equation 1, while the general version is presented 
in equation 2. Equation 1 uses an intercept estimate generated by 
the model, which is the coefficient from which the probability of 
drinking can be derived. In equation 2, a linear combination is 
used based on any deviations from the reference case in the factors 
identified as influencing alcohol consumption. An illustrative ex-
ample demonstrating the use of this equation is provided in the 
footnote of  table 1 .
Intercept
0 Intercept ,   1
e
e
p
 
(1)
 where  p 0  is the probability of consuming alcohol on a reference 
patient day (male patient, in England, not previously treated, not 
included in the SENSE trial, on a Saturday and with all continuous 
factors equal to 0), and  Intercept is a coefficient included in the 
model to represent the reference case. 
 Linear Combination
Linear Combination ,  1
e
e
p
 
(2)
 where  p  is the probability of consuming alcohol for cases other 
than the reference case and  Linear Combination is a coefficient in-
cluded in the model to represent the influences of various patient 
and other characteristics on the probability of consuming alcohol. 
The linear combination corresponds to the following formula: 
 Fig. 1. Main inputs to and output from the microsimulation 
model. 
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 β 0 + β 1 x 1 + …  +  β m x m ,  where  β i is the  i -th parameter in the logis-
tic model,  x i is the corresponding  i -th patient characteristic,  β 0 is 
the intercept, and  m the total number of parameters used in the 
model. 
 The second GLMM modelled the quantity of alcohol in grams 
consumed per day as a function of patient characteristics and oth-
er factors, including previous consumption, given that the patient 
drinks any alcohol that day. Several distribution functions were 
tested using the Akaike information criterion as quality of fit cri-
teria  [55] . It was found that the quantity of alcohol consumed in 
grams was best fitted to a negative binomial distribution  NB(r,p) , 
where  r was the number of successes achieved (alcohol not con-
sumed) and  p was the probability of a success. Similarly to the 
logarithmic equations, a linear combination was included in the 
negative binomial GLMM from which the mean amount of alco-
hol consumed could be derived. This linear equation took into ac-
count the influence of patient characteristics and drinking behav-
iour on the mean amount of alcohol consumed on a given day 
(equation 3).
 μ = e Linear Combination , (3)
 where  μ  is the mean amount of alcohol consumed and  Linear Com-
bination is a coefficient included in the model to represent the in-
fluences of various patient and other characteristics on the mean 
amount of alcohol consumed. The linear combination corre-
sponds to the following formula:  β 0 +  β 1 x 1  + … + β m x m , where  β i 
is the  i -th parameter in the negative binomial model and  x i is the 
corresponding  i -th patient characteristic,  β 0 is the intercept and  m 
 Table 1.  Coefficients of logistic model for probability of drinking
Parameter Level Estimate Standard
error
95% CI 
lower limit
95% CI 
upper limit
χ2
statistic
p
value
Odds
ratio
Intercept –1.5295 0.2182 –1.9573 –1.1018 –7.01 <0.0001 0.2166
Age (years, ref. = 0) 0.0121 0.0040 0.0043 0.0198 3.05 0.0023 1.0122
Sex (ref. = male) Female 0.1232 0.0866 –0.0465 0.2929 1.42 0.1549 1.1311
Day (ref. = Saturday) Sunday –0.6075 0.1230 –0.8485 –0.3665 –4.94 <0.0001 0.5447
Monday –0.5811 0.1280 –0.8320 –0.3302 –4.54 <0.0001 0.5593
Tuesday –0.4966 0.1179 –0.7276 –0.2657 –4.21 <0.0001 0.6086
Wednesday –0.2294 0.1219 –0.4684 0.0097 –1.88 0.0600 0.7950
Thursday –0.2279 0.1158 –0.4549 –0.0009 –1.97 0.0491 0.7962
Friday 0.1003 0.1253 –0.1453 0.3459 0.80 0.4234 1.1055
Country
(ref. = country 1)
Country 2 0.2139 0.2497 –0.2756 0.7033 0.86 0.3917 1.2385
Country 3 –0.2320 0.1477 –0.5215 0.0576 –1.57 0.1164 0.7929
Country 4 0.6219 0.1287 0.3696 0.8741 4.83 <0.0001 1.8625
Country 5 0.8142 0.2605 0.3037 1.3247 3.13 0.0018 2.2574
Country 6 –0.1257 0.2343 –0.5849 0.3335 –0.54 0.5916 0.8819
Country 7 0.4003 0.1446 0.1168 0.6838 2.77 0.0057 1.4923
Country 8 1.1172 0.1632 0.7974 1.4370 6.85 <0.0001 3.0563
Country 9 0.5463 0.2558 0.0449 1.0477 2.14 0.0327 1.7269
Countries 10, 11, 12 0.2959 0.2781 –0.2492 0.8410 1.06 0.2874 1.3443
Country 13 1.0692 0.3869 0.3110 1.8275 2.76 0.0057 2.9130
Countries 14, 15 –0.0577 0.2443 –0.5365 0.4210 –0.24 0.8131 0.9439
Country 16 1.6518 0.4911 0.6892 2.6144 3.36 0.0008 5.2164
Country 17 0.1916 0.2403 –0.2795 0.6626 0.80 0.4254 1.2112
Country 18 0.5732 0.2361 0.1105 1.0359 2.43 0.0152 1.7739
Country 19 0.0542 0.2047 –0.3470 0.4555 0.26 0.7911 1.0557
log (1 + consumption) day –1 0.3746 0.0236 0.3284 0.4209 15.88 0.3746 1.4544
log (1 + consumption) day –2 0.0676 0.0244 0.0197 0.1154 2.77 0.0676 1.0699
log (1 + consumption) day –7 0.3175 0.0238 0.2708 0.3642 13.33 0.3175 1.3737
Previously treated Yes –0.2986 0.0754 –0.4463 –0.1509 –3.96 <0.0001 0.7419
Study 12013A 0.1093 0.1353 –0.1559 0.3744 0.81 0.4192 1.1155
 Illustrative example: assuming a female patient, aged 40, from country 1, previously treated, who drank 60 g of alcohol the day be-
fore, 2 and 7 days before, the probability of drinking on a Wednesday is calculated as:
1 5295 40 0 0121 0 1232 0 2294 ln 1 60 0 3746 ln 1 60 0 0676 ln 1 60 0 3175 0 2986
1 5295 40 0 0121 0 1232 0 2294 ln 1 60 0 3746 ln 1 60 0 0676 ln 1 60 0 3175 0 2986
84 2%.
1
. . . . . . . .
. . . . . . . .
.p
e
e
×
×
×
× ×
× ×
×
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the total number of parameters used in the model. An illustrative 
example demonstrating the use of the linear combination in the 
analysis is provided in the footnote of  table 2 . 
 The resulting mean alcohol consumption was incorporated 
into the calculation for  p in the negative binomial distribution 
(equation 4).
1
1
,   1
p k
k
k
μ
 
(4)
 where  p  is the probability of not consuming alcohol,  k is the disper-
sion and  μ is the mean amount of alcohol consumed as calculated 
in equation 3. The dispersion variable  k of a random variable  Y 
following a negative binomial distribution is defined according to 
the formula:  Variance(Y) = μ +  kμ 2 . 
 Alcohol consumption data from the 28-day baseline periods 
of three Lundbeck-sponsored nalmefene phase III clinical trials 
(ESENSE1, ESENSE2 and SENSE) were available to obtain the sta-
tistical equations used in the model to simulate individual alcohol 
consumption of untreated alcohol-dependent patients.  Figure 2 
pre sents the average alcohol consumption of patients during the 
28 days before their baseline visit in the three nalmefene clinical 
trials. The clinical trials were randomised, double-blind and place-
bo-controlled studies with alcohol-dependent patients from 19 
European countries  [24–28] . These trials were used in this model-
ling context because the patient populations were those for whom 
reduction of alcohol consumption is a relevant treatment goal; spe-
cifically, alcohol-dependent patients with high DRLs without 
physical withdrawal symptoms and who do not require immediate 
detoxification, in line with nalmefene’s indication  [23, 39] . Since 
patient baseline characteristics between the three studies were sim-
Table 2. Coefficients of negative binomial model for amount of alcohol consumed on drinking days
Parameter Level Estimate Standard
error
95% CI 
lower limit
95% CI 
upper limit
χ2 
statistic
p
value
Expected 
estimate ratio
Intercept  4.9365 0.1043 4.7320 5.1410 47.32 <0.0001 139.2819
Age (years, ref. = 0)  –0.0047 0.0014 –0.0075 –0.0019 –3.33 0.0009 0.9953
Sex (ref. = male) Female –0.2298 0.0324 –0.2934 –0.1663 –7.09 <0.0001 0.7947
Day (ref. = Saturday) Sunday –0.0885 0.0137 –0.1154 –0.0617 –6.46 <0.0001 0.9153
Monday –0.1922 0.0174 –0.2262 –0.1581 –11.06 <0.0001 0.8251
Tuesday –0.1850 0.0166 –0.2176 –0.1524 –11.12 <0.0001 0.8311
Wednesday –0.1817 0.0167 –0.2145 –0.1489 –10.85 <0.0001 0.8339
Thursday –0.1847 0.0167 –0.2175 –0.1519 –11.04 <0.0001 0.8314
Friday –0.0391 0.0132 –0.0649 –0.0132 –2.96 0.0031 0.9617
Country
(ref. = country 1)
Country 2 0.0293 0.1108 –0.1879 0.2466 0.26 0.7912 1.0297
Country 3 –0.0918 0.0903 –0.2688 0.0853 –1.02 0.3098 0.9123
Country 4 –0.1645 0.0584 –0.2789 –0.0501 –2.82 0.0048 0.8483
Country 5 –0.0495 0.0943 –0.2344 0.1353 –0.53 0.5994 0.9517
Country 6 –0.1431 0.1350 –0.4077 0.1215 –1.06 0.2892 0.8667
Country 7 –0.1622 0.0652 –0.2901 –0.0344 –2.49 0.0129 0.8503
Country 8 –0.2156 0.0596 –0.3324 –0.0987 –3.62 0.0003 0.8061
Country 9 –0.2389 0.1020 –0.4388 –0.0390 –2.34 0.0192 0.7875
Countries 10, 11, 12 –0.1781 0.1211 –0.4156 0.0593 –1.47 0.1414 0.8369
Country 13 –0.1117 0.1064 –0.3201 0.0968 –1.05 0.2939 0.8943
Countries 14, 15 –0.1726 0.1242 –0.4159 0.0708 –1.39 0.1646 0.8415
Country 16 –0.1062 0.1032 –0.3084 0.0960 –1.03 0.3031 0.8992
Country 17 –0.2143 0.1321 –0.4733 0.0447 –1.62 0.1048 0.8071
Country 18 –0.2610 0.0697 –0.3976 –0.1244 –3.74 0.0002 0.7703
Country 19 –0.2388 0.1078 –0.4500 –0.0275 –2.22 0.0267 0.7876
log (1 + consumption) day –1 0.0505 0.0079 0.0350 0.0660 6.38 <0.0001 1.0518
log (1 + consumption) day –2 –0.0022 0.0072 –0.0163 0.0119 –0.31 0.7590 0.9978
log (1 + consumption) day –7 0.0386 0.0097 0.0196 0.0576 3.98 <0.0001 1.0394
Previously treated Yes 0.1209 0.0303 0.0616 0.1802 3.99 <0.0001 1.1285
Study SENSE 0.0790 0.0840 –0.0857 0.2436 0.94 0.3472 1.0822
Illustrative example: assuming a female patient, aged 60, from country 1, not previously treated, who did not drink the day before, 
who drank 80 g 2 days before and 30 g 7 days before, the predicted number of grams on a drinking Thursday would be calculated as:
μ = e4.9365 – 60 × 0.0047 – 0.2298 – 0.1847 – ln(1 + 80) × 0.0022 + ln(1 + 30) × 0.0386 = 78.5 g.
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ilar for the patient population under nalmefene’s license, data from 
these studies were pooled for use in this model.  Table 3 illustrates 
the pooled baseline patient characteristics from the nalmefene 
clinical trials for the licensed population.  Baseline characteristics 
and alcohol consumption from the 28-day baseline trial periods 
were sampled, with replacement, from trial datasets of 824 patients 
drinking at high or very high DRLs at both baseline (screening) 
and randomisation to create a model cohort of 200,000 patients. 
This patient population was the full analysis set. A simulation of 
200,000 patients was considered to provide stable results with a 
standard error of mean TAC below 0.5% of the mean.
 The model required a run-in period of at least 7 days, as the 
level of alcohol consumption on previous days was a key compo-
nent in the statistical equations. The run-in period consisted of 
individual mean consumption on each day of the second and third 
weeks of baseline clinical trial data. Although alcohol consumption 
data were available from the full 28-day baseline period, ultimate-
ly model parameters were estimated based on baseline data from 
days 8–21, as for days 1–7 previous alcohol consumption data nec-
essary for predictive purposes were not available for all patients. 
Furthermore, data from days 22–28 were found not to be predic-
tive of future alcohol consumption without treatment, as many 
patients had reduced their intake immediately prior to trial enrol-
ment in anticipation of treatment ( fig. 2 ).
 Simulation of alcohol consumption was based on random 
numbers, with the model generating two random numbers from a 
uniform distribution of 0–1 for each patient and for each day. The 
first random number was used to simulate intake of alcohol (yes 
or no); if the random number was lower than the probability of 
drinking obtained from the logistic model, the patient was as-
sumed to consume alcohol. The second random number was used 
to simulate the amount of alcohol consumed in grams, condition-
al upon a decision being made to drink. The simulated amount was 
the quantile of the distribution of alcohol consumption predicted 
by the negative binomial model corresponding to the random 
number.
 Simulating Events 
 The model outcomes were inpatient consultation episodes for 
alcohol-attributable events. Included events were those with a 
well-documented association of risk with level of alcohol con-
sumption and, based on the alcohol-dependent population includ-
ed in the nalmefene trials, those with a high incidence of hospi-
talisation in alcohol-dependent patients over a 1-year time hori-
zon. Both ‘short-term’ events, resulting from a single episode of 
heavy alcohol consumption, and ‘long-term’ events, resulting from 
continuous alcohol consumption over time, were considered in 
the model. Short-term events, such as transport injuries, other in-
juries, ischaemic heart disease and ischaemic stroke, are clinically 
most sensitive to HDDs and were modelled based on simulated 
alcohol consumption over each day. In contrast, long-term events, 
such as haemorrhagic stroke, liver cirrhosis, pancreatitis and low-
er respiratory infections, are clinically most sensitive to TAC and 
long-term consumption of alcohol, and were therefore modelled 
based on average alcohol consumption over a clinically relevant 
time period ( table 4 ).
 Two equations were used to calculate the incidence of alcohol-
attributable diseases and injuries. The first (equation 5) simply cal-
culated the general population risks of each disease or injury in-
cluded in the model, using English data. Probabilities of inpatient 
consultation episodes over the course of 1 year for the general pop-
ulation were taken from the hospital episodes statistics (HES) for 
2010–2011  [56] . Relevant ICD-10 codes were used to identify in-
patient consultation episodes for each type of disease or injury ( ta-
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 Fig. 2. Average alcohol consumption of pa-
tients during the 28 days before baseline 
visit in the three nalmefene clinical trials. 
Table 3. Pooled baseline patient characteristics from nalmefene 
clinical trials (licensed population)
Variable Value (n = 824)1
Male 565 (69)
Age, years 48.0 ± 10.8
Drinking level at baseline
High 350 (42)
Very high 474 (58)
HDDs per month at baseline, n 21.8 ± 6.2
TAC at baseline, g 104.1 ± 45.0
Data are presented as number with percentage in parentheses, 
or mean value ± SD.
1 Pooled data from ESENSE1, ESENSE2 and SENSE trials.
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Table 4. Calculation of inpatient consultation episodes for alcohol-attributable events in the model
Alcohol-
attributable
event
ICD-10 Code Source(s) for determining the 
risk relations of each disease or 
injury to level or pattern of 
alcohol consumption
Relevant time period in line 
with the physiopathology of 
the development and 
occurrence of the event
Calculation of yearly inpatient consultation 
episodes 
Transport-
related
injuries
(see footnote)1 For relative risk: Taylor et al. 
[57]
For methodology: Taylor et al. 
[51]
Daily Calculated for each patient for each day 
according to alcohol consumption in grams 
during that day. 
In line with earlier publications on harmful 
events from drinking, it was not realistic to 
assume that patients would experience increased 
risk of transport injuries and injuries other than 
transport for the entire day, because patients 
must be in a specific environment to experience 
the event [11, 50]. Thus, an adjustment of hours 
drinking per day was incorporated into the 
model’s calculations for these events. In the 
analysis, the hours of drinking per day and thus 
the time the patient is subject to a risk of 
experiencing the event is therefore set to 3 h.
The number of inpatient consultation episodes 
over 12 months was obtained by summing daily 
probabilities of inpatient consultation episodes.
Non-
transport-
related
injuries
Rest of V-series2,
W00–W99, 
X00–X39, X40–X84,
X85–Y09, Y40–Y86,
Y87.0, Y87.1, Y88
and Y89
For relative risk: Taylor et al. 
[57]
For methodology: Taylor et al. 
[51]
Daily Calculated in the same manner as for transport-
related injuries.
Ischaemic
stroke
I60–I62 Patra et al. [45]
For pattern of alcohol 
consumption: Guiraud et al. 
[46]
Daily Calculated for each patient for each day 
according to alcohol consumption in grams 
during that day. The model therefore accounts 
for occurrences triggered by significant daily 
alcohol consumption. The number of inpatient 
consultation episodes over 12 months was 
obtained by summing daily probabilities of 
inpatient consultation episodes.
Ischaemic
myocardial
infarction
I20–I25 For pattern of alcohol 
consumption: Roerecke and 
Rehm [43]
For volume of alcohol 
consumption: Roerecke and 
Rehm [58]
Daily Calculated in the same manner as for ischaemic 
stroke, as both events have similar 
physiopathologies of occurrence, and have 
shown similar risks epidemiologically for being 
triggered by heavy drinking.
Liver
cirrhosis
K70, K74 Rehm et al. [47] Two 6-month periods Calculated for each patient over two 6-month 
periods, to account for the progressive 
development of the condition with alcohol 
consumption. Average daily consumption was 
estimated over the two periods and the relative 
risk determined at the end of each period. The 
number of inpatient consultation episodes over 
12 months was obtained by summing the 
probabilities over the two 6-month periods.
Pancreatitis K85, K86.1 Irving et al. [48] Two 6-month periods Calculated in the same manner as for liver 
cirrhosis. The model did not distinguish between 
acute and chronic pancreatitis, with inpatient 
consultation episodes for acute and chronic 
pancreatitis combined and the same relative risk 
function applied to both types of event.
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ble 4 ). Specifically, the HES variable ‘finished consultant episodes’ 
(FCE) was used, which represents an episode of care under the 
supervision of one consultant, and can be used as a proxy for the 
number of diagnoses of alcohol-attributable diseases or injuries 
during hospital stays. For injuries, the denominator was the total 
male and female population size in England in 2010, while for dis-
eases the denominator was the number of males and females aged 
18 years or over in England in 2010, since few relevant disease-
related episodes were recorded in children. The risks for males and 
females were calculated separately.
Number of events over 1 year
General Population s Disease Risk( ) .  
Country s total population
’
’
i
 
(5)
 Published meta-analyses assessing the impact of alcohol con-
sumption were used to develop risk equations to calculate the rela-
tive risks of disease and injury for patients with a given daily alcohol 
consumption compared to the general population  [43, 45, 47–49, 
51, 57, 58] . These risk equations were developed by the Canadian 
Centre for Addiction and Mental Health (CAMH) using published 
meta-analyses based on systematic literature reviews that included 
international literature ( table  4 ), and were previously used for a 
population-based analysis  [16] . Calculated relative risk ratios at a 
given level of alcohol consumption were then multiplied by the risk 
of the event in the general population derived in equation 5 (equa-
tion 6). The risk ratio was applied considering alcohol consump-
tion over a time period in accordance with the physiopathology of 
the development and occurrence of the event; for example, grams 
of alcohol consumed per day, average daily consumption over the 
previous month, or average daily consumption over the previous 6 
months ( table 4 ). Probabilities of clinical events for each patient 
were summed over 12 months and then aggregated over groups of 
patients defined by the number of HDDs and TAC across 12 
months. This was performed for men and women separately, and 
then combined based on the proportions of males and females in 
the nalmefene clinical trials. An illustrative example of how the risk 
equations were implemented in the model is given for liver cirrho-
sis in online supplementary table 1 (for all online suppl. material, 
see www.karger.com/doi/10.1159/000362408). 
 Personal Disease Risk(i) T1 Patient (z) 
 = General Population’s Disease Risk(i)
× RRDisease(i)(x T1 )Patient z , (6)
 where Personal Disease Risk( i ) T1 Patient (z)  is the risk of disease ( i ) 
for a time  T1 for Patient z , and RRDisease( i )( x T1 )Patient z is the rel-
ative risk of disease ( i ) given an alcohol consumption at time  T1 of 
 x grams for a  Patient z with AD, versus the general population. 
 Sensitivity Analysis 
 Deterministic sensitivity analyses were conducted by varying 
statistically uncertain parameters of the relative risk equations 
used to derive the incidence of alcohol-attributable events accord-
ing to the level of alcohol consumption. The analyses were run us-
ing the lower bound of variance of all relative risk function param-
eters with statistical uncertainty simultaneously, and then the up-
per bound of the variance of all such parameters simultaneously. 
When different functions were used for males and females, param-
eters were changed for males and females simultaneously.
 Uncertainty around the parameters of the logistic and negative 
binomial regression models was assessed by a probabilistic sensi-
tivity analysis. Each parameter was associated to a normal distribu-
tion with a mean equal to the value of the estimate (‘Estimate’ col-
umn in  tables 1 and  2 ) and using the standard error around the 
estimate (‘Standard error’ column in  tables 1 and  2 ). The alcohol 
consumption of 200,000 patients was then simulated, as well as 
their alcohol-related events. Confidence intervals around the 
number of events were produced using 2.5 and 97.5 percentiles of 
the results of the simulations.
 External Validation of Results 
 An external validation of the model results was performed, 
with the incidence of hospitalisation events in the alcohol-depen-
dent population calculated using equation 7. For the external vali-
dation, the relative risks of alcohol-attributable events were de-
rived from a single source in the published literature for each 
event, as opposed to being based on a risk formula developed from 
meta-analysis. Data on the incidence of disease events in the UK 
general population in terms of inpatient admission rates were tak-
Haemorrhagic
stroke
I63–I66 Patra et al. [45] Two 6-month periods Calculated in the same manner as for liver 
cirrhosis.
Lower 
respiratory
infection
J10–J18, J20–J22 Samokhvalov et al. [49] Twelve 1-month periods Average daily consumption was estimated for 
each patient over twelve 1-month periods and 
the relative risk determined at the end of each 
period. The number of inpatient consultation 
episodes over 1 year was obtained by summing 
the probabilities over the twelve periods.
1 V021–V029, V031–V039, V041–V049, V092, V093, V123–V129, V133–V139, V143–V149, V194–V196, V203–V209, V213–V219, V223–V229, V233–
V239, V243–V249,V253–V259, V263–V269, V273–V279, V283–V289, V294–V299, V304–V309, V314–V319, V324–V329, V334–V339, V344–V349, 
V354–V359, V364–V369, V374–V379, V384–V389, V394–V399, V404–V409, V414–V419, V424–V429, V434–V439, V444–V449, V454–V459, V464–
V469, V474–V479, V484–V489, V494–V499, V504–V509, V514–V519, V524–V529, V534–V539, V544–V549, V554–V559, V564–V569, V574–V579, 
V584–V589, V594–V599, V604–V609, V614–V619, V624–V629, V634–V639, V644–V649, V654–V659, V664–V669, V674–V679, V684–V689, V694–
V699, V704–V709, V714–V719, V724–V729, V734–V739, V744–V749, V754–V759, V764–V769, V774–V779, V784–V789, V794–V799, V803–V805, 
V811, V821, V830–V833, V840–V843, V850–V853, V860–V863, V870–V878, V892. 
2 V series minus footnote 1.
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en from the European Hospital Morbidity Database (HMDB)-
WHO Regional Office for Europe  [59] . Diseases were identified 
with the same ICD-10 codes as used in the model. The incidences 
of events estimated in this way were compared with the incidences 
of events obtained in the model.
 Incidence of hospitalisation events in the alcoholic population
 = Relative risk associated with alcohol consumption × 
 Incidence of hospitalisation events in the general population. (7)
 Results 
 Simulating Alcohol Consumption – Probability of 
Consuming Alcohol 
 The clinical trials used in the run-in period of the mod-
el provided data for 11,536 patient days, including 9,888 
drinking days. The logistic model for probability of drink-
ing was estimated based on these data ( table 1 ). In the 
model, the probability of drinking significantly increased 
with age (odds ratio = 1.0122, meaning that the odds of 
drinking increased by approximately 1.22% with each ad-
ditional year of age when all other parameters were equal). 
However, there was no significant difference between the 
sexes. In the model, the probability of drinking was high-
er on Fridays, with the odds of drinking being 10.6% 
higher on Fridays compared to Saturdays, and 20.4–
45.5% lower on other days. Odds of drinking were re-
duced by 25.8% in previously treated patients compared 
to treatment-naïve patients. There was significant vari-
ability between countries in the probability of drinking. 
All other parameters were non-significant, but were 
maintained in the model for adjustment purposes.
 Simulating Alcohol Consumption – Amount of 
Alcohol Consumed 
 The negative binomial model for the amount of alco-
hol consumed on drinking days was estimated based on 
data describing 9,888 drinking days from the run-in pe-
riod ( table 2 ). The model was run without random patient 
effects initially, in order to estimate the dispersion. The 
dispersion parameter was estimated at 1.2667. In the 
model, the coefficient of age was negative, implying that 
the mean quantity of alcohol consumed on drinking days 
decreased with age. The associated ratio of 0.9953 meant 
that consumption was reduced by 0.47% with each year 
of age. The model also showed that female patients drank 
20.5% less compared to males on an average drinking day, 
all other parameters being equal.
 In the model, the quantity of alcohol consumed was 
highest on Saturdays, conditional upon drinking, with 
consumed quantities 3.8% (Friday) to 17.5% (Monday) 
lower on other days. The quantity of alcohol consumed 
varied between countries, being 23.0% lower in the 
country with the lowest daily consumption compared to 
the reference country. The quantity of alcohol con-
sumed increased with consumption on the previous day 
and on the same day of the previous week. For example, 
the mean quantity of alcohol was 27.6% higher in a pa-
tient who drank 123 g on the previous day (average con-
sumption on a drinking day) compared to a patient who 
did not drink, all other parameters being equal. Finally, 
previously-treated patients drank 12.9% more than 
treatment-naïve patients, all other parameters being 
equal.
 Clinical Relevance of a Reduction in the Number of 
HDDs per Year 
 For all diseases and injuries, the number of events in-
creased with the number of HDDs per year for the whole 
simulated cohort of untreated alcohol-dependent pa-
tients ( table  5 ). In mixed model repeated measures 
(MMRM) analyses of the nalmefene clinical trials, the 
number of HDDs per month in patients receiving nal-
mefene fell from 23 at baseline to 11 at month 6 in 
 ESENSE1  [28] , from 23 at baseline to 10 at month 6 in 
ESENSE2  [28] , and from 19 at baseline to 7 at month 13 
in SENSE  [25] . The predictive microsimulation model 
suggested that a reduction from 23 HDDs per month to 
10 or 11 HDDs per month (the equivalent of a reduction 
from >220 HDDs per year to 120–140 HDDs per year), as 
seen in ESENSE1 and ESENSE2, would result in the an-
nual avoidance of 6,813 (95% CI 6,466–6,847) alcohol-
attributable diseases and injuries in a cohort of 100,000 
alcohol-dependent patients. This figure comprised 481 
(95% CI 478–484) events of ischaemic heart disease, 152 
(95% CI 150–152) events of ischaemic stroke, 357 (95% 
CI 352–358) events of traffic-related injuries, 2,140 (95% 
CI 2,126–2,148) events of non-traffic-related injuries, 873 
(95% CI 836–883) events of liver cirrhosis, 2,016 (95% CI 
1,734–2,030) events of pancreatitis, 659 (95% CI 643–
671) events of lower respiratory infection and 135 (95% 
CI 132–137) events of haemorrhagic stroke. The numbers 
of avoided events were similar when estimating the clini-
cal relevance of reductions in HDDs as observed with nal-
mefene in the SENSE trial: a reduction of 19 HDDs per 
month (>220 HDDs per year) to 7 HDDs per month 
(<100 HDDs per year) was predicted to result in the an-
nual avoidance of 9,004 (95% CI 8,656–9,038) alcohol-
attributable diseases and injuries per 100,000 alcohol-de-
pendent patients.
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CI 933–945) alcohol-attributable diseases and injuries 
per 100,000 alcohol-dependent patients, comprising 109 
(95% CI 109–110) events of ischaemic heart disease, 34 
(95% CI 34–34) events of ischaemic stroke, 66 (95% CI 
65–66) events of traffic-related injuries, 510 (95% CI 507–
513) events of non-traffic-related injuries, 77 (95% CI 75–
77) events of liver cirrhosis, 56 (95% CI 54–56) events of 
pancreatitis, 74 (95% CI 71–74) events of lower respira-
tory infection and 15 (95% CI 15–16) events of haemor-
rhagic stroke.
 Clinical Relevance of a Reduction in TAC per Year 
 For all diseases and injuries, the number of events in-
creased as TAC per year increased for the whole simu-
 At the end of the nalmefene clinical studies, in MMRM 
analyses the difference in the number of HDDs per month 
between nalmefene and placebo was 3.7 in ESENSE1  [28] , 
2.7 in ESENSE2  [28] and 3.6 in SENSE  [25] . Assuming a 
conservative reduction in alcohol consumption achieved 
with nalmefene versus placebo of 2–3 HDDs per month 
(conservatively corresponding to 20 HDDs per year), the 
model was used to estimate the difference between the 
number of events in a cohort of 100,000 alcohol-depen-
dent patients with 120–140 HDDs per year (equivalent to 
the mean number of HDDs per year in the ESENSE1 
 nalmefene arm at month 6) and a cohort of 100,000 alco-
hol-dependent patients in the adjacent, higher category 
of 140–160 HDDs per year. The difference was 941 (95% 
Table 5. Number of events per 100,000 patient years by number of HDDs (males and females)
HDDs per
year, days
Ischaemic 
heart disease
Ischaemic
stroke
Traffic
injuries
Other 
injuries
Cirrhosis Pancreatitis Lower respiratory
infection
Haemorrhagic
stroke
<100 1,563 494 303 2,434 330 141 1,827 149
100 – 120 1,707 538 398 3,085 428 188 1,957 171
120 – 140 1,819 572 465 3,602 505 235 2,046 188
140 – 160 1,928 606 531 4,112 582 291 2,120 203
160 – 180 2,027 637 598 4,553 686 391 2,217 223
180 – 200 2,118 666 668 4,953 836 596 2,340 248
200 – 220 2,211 695 747 5,361 1,084 1,136 2,523 284
>220 2,300 724 822 5,742 1,378 2,251 2,705 323
This table was presented in the nalmefene European public assessment report [39].
 Table 6.  Number of events per 100,000 patient years by TAC category per year (males and females)
TAC per year, g Ischaemic heart
disease
Ischaemic
stroke
Traffic
injuries
Other
injuries
Cirrhosis Pancreatitis Lower respiratory
infection
Haemorrhagic 
stroke
<15,000 1,465 467 239 2,034 269 116 1,731 134
15,000 – 18,000 1,562 498 304 2,492 322 132 1,812 149
18,000 – 21,000 1,640 524 358 2,881 370 150 1,879 161
21,000 – 24,000 1,721 551 412 3,278 424 175 1,950 174
24,000 – 27,000 1,810 579 467 3,691 483 206 2,022 189
27,000 – 30,000 1,895 605 519 4,071 548 248 2,095 204
30,000 – 33,000 1,964 626 568 4,383 621 303 2,173 221
33,000 – 36,000 2,024 645 613 4,652 703 380 2,254 239
36,000 – 39,000 2,076 661 655 4,887 794 485 2,340 259
39,000 – 42,000 2,122 675 693 5,089 899 636 2,435 280
42,000 – 45,000 2,157 686 726 5,248 1,017 866 2,528 303
≥45,000 2,216 704 773 5,508 1,234 1,435 2,691 336
This table was presented in the nalmefene European public assessment report [39].
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lated cohort of untreated alcohol-dependent patients ( ta-
ble  6 ). Again, these results were assessed in terms of 
MMRM results from the three nalmefene phase III clini-
cal trials for the licensed population. In ESENSE1, mean 
TAC in patients receiving nalmefene was 102 g/day at 
baseline compared to 44 g/day at the end of the study  [28] , 
corresponding to the annual TAC categories of 36,000–
39,000 g and 15,000–18,000 g, respectively. The model 
estimated that the difference between these two cohorts 
over the course of 1 year was 4,886 (95% CI 4,882–4,904) 
events per 100,000 alcohol-dependent patients. As with 
HDDs, a large number of these events were non-traffic-
related injuries (2,396; 95% CI 2,392–2,406), with the rest 
comprising ischaemic heart disease (514 events; 95% CI 
514–517), ischaemic stroke (163 events; 95% CI 163–
164), traffic-related injuries (351 events; 95% CI 349–
351), liver cirrhosis (472 events; 95% CI 472–473), pan-
creatitis (353 events; 95% CI 352–354), lower respiratory 
infection (528 events; 95% CI 528–531) and haemor-
rhagic stroke (110 events; 95% CI 110–110).
 The numbers of avoided events were similar when 
considering data from ESENSE2 and SENSE. In 
ESENSE2, mean TAC in nalmefene-treated patients de-
creased from 113 g/day at baseline to 43 g/day at the end 
of the study, corresponding to the annual TAC categories 
of 39,000–42,000 g and 15,000–18,000 g, respectively 
 [28] . The model estimated that the difference between 
these two cohorts over the course of 1 year was 5,558 (95% 
CI 5,533–5,566) events per 100,000 alcohol-dependent 
patients. In SENSE, mean TAC in nalmefene-treated pa-
tients was 100 g/day at baseline and 33 g/day at the end of 
the study  [25] . The difference between the annual TAC 
categories of 36,000–39,000 g and <15,000 g that these 
daily consumptions correspond to were estimated to re-
sult in the annual avoidance of 5,702 (95% CI 5,695–
5,725) alcohol-attributable events per 100,000 alcohol-
dependent patients in the model.
 At the end of the nalmefene clinical studies, the differ-
ences in TAC by MMRM analysis between nalmefene and 
placebo were 18.3 g/day, 10.3 g/day and 17.3 g/day in 
 ESENSE1, ESENSE2 and SENSE, respectively  [25, 28] . 
Assuming a conservative reduction in alcohol consump-
tion achieved with nalmefene versus placebo of 10 g/day 
(conservatively corresponding to 3,000 g/year), the pre-
dictive microsimulation model estimated that between 
patients in the 15,000–18,000 g/year category (equivalent 
to mean TAC per year in the ESENSE1 nalmefene arm at 
the end of the trial) and the 18,000–21,000 g/year catego-
ry, there would be an annual difference of 692 (95% CI 
678–698) alcohol-attributable diseases and injuries per 
100,000 alcohol-dependent patients. This figure consist-
ed of 78 (95% CI 76–79) events of ischaemic heart disease, 
26 (95% CI 25–26) events of ischaemic stroke, 54 (95% CI 
52–54) events of traffic-related injuries, 389 (95% CI 378–
392) events of non-traffic-related injuries, 48 (95% CI 48–
49) events of liver cirrhosis, 18 (95% CI 18–19) events of 
pancreatitis, 67 (95% CI 67–70) events of lower respira-
tory infection and 12 (95% CI 12–12) events of haemor-
rhagic stroke.
 Sensitivity Analyses 
 In all deterministic sensitivity analyses, varying statis-
tically uncertain parameters of the relative risk equations 
used to derive the incidence of alcohol-attributable events 
according to the level of alcohol consumption resulted in 
the numbers of events per 100,000 patient years increas-
ing accordingly with the number of HDDs and TAC per 
year, consistent with the base case results (online suppl. 
tables 2 and 3). For all diseases and injuries, the difference 
in numbers of events per 100,000 patient years using the 
minimum and maximum parameter values increased in 
categories with higher HDDs and TAC. For both HDDs 
and TAC, the events with the largest ranges between min-
imum case and maximum case were non-transport-relat-
ed injuries, pneumonia and pancreatitis. Even in the min-
imum case scenarios for all diseases and injuries, the 
number of events avoided by reducing HDD and TAC 
remained considerable. For example, using the minimum 
case scenarios for females for all alcohol-attributable 
events, a reduction in annual TAC from the 36,000–
39,000 g/year category to the 15,000–18,000 g/year cate-
gory, as seen from baseline to the end of the trial in the 
nalmefene arm in ESENSE1, still predicted 2,280 events 
per 100,000 patient years being avoided overall, with the 
lowest number of events avoided being predicted for isch-
aemic strokes (55 events). For males, this same reduction 
in annual TAC was estimated to result in 2,547 events per 
100,000 patient years avoided overall, with the lowest 
number of events avoided being predicted for haemor-
rhagic stroke (42 events).
 In the probabilistic sensitivity analysis assessing the 
parameters used in the alcohol consumption equations, 
2.5 and 97.5 percentiles of the results in terms of number 
of events per 100,000 patient years are presented in online 
supplementary tables  4 and 5. These intervals demon-
strate a relatively small distribution of the results, ex-
plained by the statistical power resulting from 11,536 pa-
tient days and 9,888 drinking days provided by using data 
sourced from the nalmefene clinical trials for simulating 
alcohol consumption. For both HDDs and TAC, the 
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events with the largest ranges between minimum and 
maximum case were non-transport-related injuries, liver 
cirrhosis and pancreatitis.
 External Validation 
 A comparison of hospitalisation events predicted by 
the external validation and by the model is provided in 
 table 7 . Compared to the external validation results, the 
model predicted slightly higher numbers of events for 
lower respiratory infection and ischaemic heart disease 
(ratio of model results to external validation results  ∼ 1.5) 
and lower numbers of events for ischaemic stroke and cir-
rhosis in men (ratio  ∼ 0.7). However, the model and the 
external validation predicted similar numbers of events 
for haemorrhagic stroke, injury, pancreatitis and cirrho-
sis in women (ratio 0.8, 0.9, 1.0 and 1.2, respectively).
 Discussion 
 Results from this microsimulation model have indi-
cated that the risks of experiencing ischaemic heart dis-
ease, ischaemic and haemorrhagic stroke, cirrhosis, pan-
creatitis, lower respiratory infection, traffic-related inju-
ries and non-traffic-related injuries vary considerably 
with the frequency of HDDs and TAC per month in pa-
tients with AD. To contextualise these results, the model 
predicted that a 20-day per year reduction in the number 
of HDDs, as achieved with nalmefene compared with pla-
cebo in clinical trials, would be associated with a clini-
cally relevant reduction in the number of harmful alco-
hol-attributable events per 100,000 patient years. Simi-
larly, a 3,000 g/year reduction in TAC, again as achieved 
with nalmefene versus placebo in clinical trials, was pre-
dicted to result in a clinically relevant reduction in the 
incidence of harmful events. All model outcomes were 
 Table 7.  Number of predicted hospitalisation events using data from a targeted review of the literature and WHO-HMDB compared to 
the model
Disease or injury External validation (targeted literature search + WHO-HMDB)  Model
source of relative
risk estimate
alcohol level,
g/day
relative risk1 events in general
population2, n
events in alcoholic
population3, n
events in alcoholic 
population4, n
Ischaemic heart
disease
Roerecke and Rehm 
[43], 2010 >60 1.45 518 751 ~1,100 – 1,200
Ischaemic stroke Reynolds et al. [69], 
2003 >60 1.69 201 340 ~250
Injury 
(traffic + others)
Corrao et al. [70],
1999 100 4.00 1,207 4,827 ~4,300
Liver cirrhosis 
(men)
Rehm et al. [47], 
2009 >60 5.00 59 295 ~200
Liver cirrhosis 
(women)
Rehm et al. [47], 
2009 >60 6.10 31 189 ~200 – 250
Pancreatitis Irving et al. [48],
2009 100 4.50 69 311 ~300
Lower respiratory
infection
Rehm et al. [14], 
2010 100 1.61 618 995 ~1,400
Haemorrhagic 
stroke
Reynolds et al. [69], 
2003 >60 2.18 58 126 ~100
 1 Depending on data available, relative risk for >60 g/day or >100 g/day 
alcohol consumption. 2 Number of hospitalisation events per 100,000 patient 
years in the UK general population, Europe WHO-HMDB. 3 Number of pre-
dicted hospitalisation events per 100,000 patient years in the UK alcoholic 
population (relative risk × number of events in the general population). 
4 Number of predicted hospitalisation events per 100,000 patient years in 
English alcohol-dependent population. Depending on relative risk informa-
tion available in the external validation, figures are provided for the 18,000 – 
24,000 TAC/year category (~60 g/day) or the 33,000 – 39,000 TAC/year cate-
gory (~100 g/day). Ratio HES finished consultant episodes/admissions ap-
plied for correction: in the WHO-HMDB, events reported were ‘inpatient 
admission rates’, so to be as comparable as possible in the external validation, 
events for the model were issued from the HES variable ‘admissions’ (for 
model implementation, the HES variable ‘FCE’ was used).
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robust to sensitivity analysis and were validated using ex-
ternal data sources.
 While these findings are in line with previous popula-
tion-level studies investigating the impact of alcohol re-
duction on mortality  [29–33] , to our knowledge this is the 
first study to quantitatively model the association be-
tween morbidity and the level of alcohol consumption for 
alcohol-dependent patients at the individual level. It cor-
roborates recent results from meta-analyses of cohort 
studies that reduction of drinking in people with alcohol 
problems  [34, 60] and reduction of drinking in people be-
ing treated for AD may result in significant mortality 
gains  [61] . However, the latter study was unable to mea-
sure the association between the level of reduction of 
drinking and mortality as the underlying literature did 
not contain this information.
 Given the recent acknowledgement of alcohol reduc-
tion as a valid treatment goal for alcohol-dependent pa-
tients by the EMA  [19] , this study is timely in demonstrat-
ing the clinical relevance of treatments successfully affect-
ing reductions in alcohol consumption, such as nalmefene. 
During the EMA marketing authorisation process for 
 nalmefene, this predictive microsimulation model and 
the model results were presented to the CHMP. The Sci-
entific Advisory Group noted that the model showed that 
‘even a moderate decrease in drinking levels might be as-
sociated with a decrease in both harmful events (e.g. mor-
tality rates, accidents) and a decrease in the relative risk 
of the medical issues typically linked to excessive alcohol 
drinking (e.g. liver cirrhosis)’  [39] .
 This study employed a predictive microsimulation 
modelling approach, which is novel in this therapeutic 
area. Such an approach is well suited when modelling al-
cohol-dependent patients as the relationships between al-
cohol consumption per time period and risks of disease 
are non-linear, necessitating the accurate simulation of 
the drinking patterns of individual patients. Microsimu-
lation also allowed for heterogeneity in consumption be-
tween individual patients. It was recently reported that 
such an approach is being employed by the Organisation 
for Economic Cooperation and Development (OECD) to 
evaluate the cost-effectiveness of interventions for AD 
 [62] . An alternative approach to the microsimulation 
method used here would have been to use a health state-
transition model, such as Markov chains; future work in 
our group will entail a comparative assessment of model-
ling approaches for predicting the clinical relevance of 
reducing alcohol consumption.
 Rather than use simple regression, alcohol consump-
tion was modelled using a two-part model. In the litera-
ture, two-part models tend to be preferred to linear re-
gression from a statistical perspective when the data con-
sist of a mixture of zero values and continuous positive 
values. This is because two-part models help to distin-
guish between using zero as a value in itself and not also 
as a substitute for negative or missing data  [63, 64] . Fur-
thermore, simple regression is only able to predict posi-
tive alcohol consumption, whereas a large proportion of 
patients do not drink every day. Thus, the present model 
of alcohol consumption is a more accurate representation 
of real-life drinking patterns.
 The selection of England as the reference country in 
the model was a result of good quality English data being 
available for the probabilities of inpatient consultation 
episodes for each alcohol-attributable disease or injury. 
These data were used to estimate the baseline risk of each 
event for the general population. The use of FCE data may 
have led to overestimation of the number of inpatient al-
cohol-attributable diseases or injuries, as patients may be 
hospitalised more than once during a single year for the 
same problem, or be transferred from the care of one con-
sultant to another for specialist treatment or diagnosis. 
However, the objective of the model was to estimate the 
number of alcohol-attributable events necessitating hos-
pitalisation, not the number of patients with alcohol-at-
tributable events.
 While the model was developed with England as the 
reference case, the nalmefene clinical trial data used to 
model alcohol consumption also included patients from 
other European countries. This could have introduced bias 
in the model since patterns of drinking can vary between 
countries  [7] . Drinking patterns in England are considered 
to feature a higher number of intermittent episodes of 
heavy drinking compared with some other European 
countries where more constant levels of moderate drink-
ing are seen  [16] . Therefore, it is likely that, relative to the 
English setting, the model results may have underestimat-
ed the incidence of events influenced by short-term heavy 
drinking, such as ischaemic stroke, and overestimated the 
incidence of events that are more dependent on continu-
ous alcohol consumption over time. On the other hand, 
use of alcohol consumption data from European-wide 
clinical trials and the development of risk algorithms based 
on systematic literature reviews, including international 
literature, may, to some extent, allow the model results to 
be generalised to a pan-European or even global context.
 While the model took into account the relative risk of 
different events over different clinically relevant time pe-
riods (1 day, 1 or 6 months), it did not take into account 
the conditional probabilities of events based on previous 
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occurrence of the same or other diseases. The relationship 
between alcohol consumption and the probability of in-
jury was also simplified; blood alcohol concentration, 
which depends not only on how much a person drinks 
but also on the duration of time over which alcohol is 
consumed, is known to be a better predictor of the prob-
ability of an accident during a drinking day than the total 
amount of alcohol consumed that day. In order to com-
pensate for this limitation, the increased risk of injuries 
associated with drinking was assumed to apply over a pe-
riod of 3 h per drinking day within the base case. This ap-
proach has previously been used in other studies assess-
ing the risk of accidents associated with alcohol con-
sumption  [11, 50] .
 Despite the limitations of the model discussed, it is 
likely that the results reported are conservative and may 
underestimate the beneficial impact of reducing alcohol 
consumption. For example, while an extensive list of con-
ditions has been established as alcohol attributable  [65] , 
not all could be considered in the model due to the time 
horizon of the analysis and the availability of data. The 
alcohol-attributable events selected for inclusion in the 
model were those with a strong published evidence base 
demonstrating an association between alcohol consump-
tion and risk, and those shown to have a high incidence 
of hospitalisation over a 1-year time horizon in the popu-
lation of alcohol-dependent patients modelled and for 
which nalmefene is licensed. Thus, even though there is a 
strong relationship between alcohol consumption and, 
for example, cancer  [66, 67] , these risks were not mod-
elled as there is a longer time lag between alcohol con-
sumption and cancer incidence than that considered in 
the nalmefene clinical trials. Furthermore, as ‘events’ 
were defined as inpatient hospitalisation episodes, it 
should be noted that the model does not account for the 
full burden of AD, as any cases of alcohol-attributable in-
jury or disease not warranting hospitalisation were ig-
nored. It should finally be noted that the model did not 
take into account the social burden of alcohol misuse; as 
the cost of criminal justice associated with alcohol misuse 
is estimated to represent almost a quarter of public sector 
resource costs in the UK  [68] , this would be expected to 
present an added benefit of reducing alcohol consump-
tion.
 The model had good internal and external validity, 
making use of risk equations that have previously been 
used and validated in estimating the burden of alcohol 
abuse in terms of disability-adjusted life years and mor-
tality in various regions of the world  [11, 13, 16, 35] . The 
external validation demonstrated that the model outputs 
(number of inpatient consultation events) were closely 
aligned with existing published evidence. A simple calcu-
lation, based on a single alcohol-attributable relative risk 
for each event and an alternative source of data for 
the number of events in the general population (WHO-
HMDB), supported the magnitude of the outcomes of the 
risk equations used in the model. The validation process 
was subject to a number of limitations, including the fact 
that the national statistics referenced for the model 
through the HES database included only events reported 
in England, whereas for the external validation WHO-
HMDB data could only be obtained for the UK as a whole. 
In addition, a correction of the ratio of HES FCE (used in 
the baseline model) to the ‘admissions’ variable (used in 
the external validation) had to be applied to allow a com-
parison between the baseline model risk and baseline 
WHO-HMDB risk. As the objective of the external vali-
dation exercise was to allow a rough comparison with 
published data, these limitations were deemed accept-
able.
 This study demonstrates that the number of alcohol-
attributable diseases and injuries increases with TAC and 
the number of HDDs per time period, indicating that 
harm reduction by reducing alcohol consumption is a 
valid treatment goal for alcohol-dependent patients. 
Harm reduction has the added benefit of potentially ap-
pealing to patients who may otherwise have been unwill-
ing to commit to treatment that is essential from both a 
societal and public health perspective. Increasing the pro-
vision of treatments for AD, including those designed to 
support harm reduction, may therefore have profound 
implications for clinical health burden at the individual 
and European level  [6] . However, it should be remem-
bered that this model used pre-treatment alcohol con-
sumption data. While this approach was deemed appro-
priate for assessing the health consequences of reducing 
alcohol consumption in the nalmefene marketing au-
thorisation by the EMA Scientific Advisory Group  [39] , 
contextualising the clinical relevance of alcohol reduction 
using the nalmefene clinical trial results relies on the as-
sumption that patients’ drinking patterns during the run-
in period were representative of longer-term drinking 
patterns. While the model run-in period was limited to 
using 2 weeks of data from the nalmefene clinical trials, 
this provided data for 11,536 patient days, including 
9,888 drinking days, which carried sufficient statistical 
power for the statistical analysis in itself. Nevertheless, 
this use of short-term data to model longer-term drinking 
behaviour represents a limitation of the analysis, and re-
sults should only be used as a proxy to evaluate the clini-
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cal relevance of alcohol reduction that could be antici-
pated with nalmefene. The best way to ascertain the clin-
ical relevance of reducing alcohol consumption with 
nalmefene would be to reproduce the patterns of drinking 
observed during the clinical trials, an analysis currently 
being undertaken by our group.
 This novel microsimulation modelling approach has 
made it possible to translate reductions in alcohol con-
sumption in alcohol-dependent patients into harm re-
duction in terms of alcohol-attributable events avoided. 
The results of this model could be considered the best 
possible estimation of the changes in risk associated with 
variation in alcohol consumption levels, and the potential 
benefits to be gained by supporting alcohol-dependent 
patients in reducing their alcohol consumption effec-
tively.
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